Bevacizumab injection, marketed under the brand name “Abevmy,” is a targeted oncology medication used in the treatment of various advanced cancers. Abevmy contains Bevacizumab 400 mg, a recombinant humanized monoclonal antibody that works by inhibiting tumor blood vessel formation, helping to slow cancer growth and progression.

Abevmy injection is widely used by hospitals, oncology centers, cancer treatment clinics, pharmaceutical distributors, and healthcare providers across international markets. Due to the increasing demand for targeted cancer therapies, Bevacizumab has become an essential medicine in modern oncology treatment protocols.

As a reliable pharmaceutical exporter from India, we offer export-quality Abevmy 400 mg injections with secure packaging, temperature-controlled logistics support, bulk supply capability, competitive pricing, and worldwide delivery solutions.

Mechanism of Action

Bevacizumab works by targeting and binding to Vascular Endothelial Growth Factor (VEGF), a protein responsible for promoting the formation of new blood vessels that supply nutrients and oxygen to tumors.

By blocking VEGF activity, Bevacizumab inhibits angiogenesis (new blood vessel formation), reducing blood supply to cancer cells and slowing tumor growth. This targeted approach helps improve treatment outcomes when used alone or in combination with chemotherapy and other anticancer therapies.

Uses of Abevmy 400 mg (Bevacizumab) Injection

Abevmy injection is commonly prescribed for:

• Metastatic colorectal cancer
• Non-small cell lung cancer (NSCLC)
• Recurrent glioblastoma
• Metastatic renal cell carcinoma (kidney cancer)
• Cervical cancer
• Ovarian cancer
• Fallopian tube cancer
• Peritoneal cancer
• Advanced and metastatic solid tumors as part of combination therapy
  

  Common Adverse Effects:

  • High blood pressure
  • Fatigue and weakness
  • Headache
  • Nosebleeds
  • Protein in urine
  • Diarrhea
  • Nausea and vomiting
  • Loss of appetite
  • Infusion-related reactions